Only 25 spots left for Owner Summit – register now!
There are only 25 spots left for the professional development event of the year for compounding pharmacy and facility owners and managers.
There are only 25 spots left for the professional development event of the year for compounding pharmacy and facility owners and managers.
In an open letter released yesterday, drugmaker Eli Lilly had plenty to say about compounded GLP-1s, and – surprise! – not all of it accurate.
The APC Board of Directors has authorized release of a public statement, Understanding Law and Regulation Governing the Compounding of Peptide Products.
A new NCPA survey reveals local pharmacies are struggling to stay afloat after the January 1 implementation of the CMS DIR rule, requiring all pharmacy price concessions (i.e., DIR fees) to be assessed at the point of sale.
The Florida Board of Pharmacy Compounding Subcommittee met last week to discuss the state’s USP 797 inspection process.
The Massachusetts Board of Registration in Pharmacy held a hearing February 28 on proposed new fees for pharmacy licenses in the state.
A couple of years ago, APC released a brief for prescribers on peptide compounding. The title of that brief was “Compounded Peptides: It’s Complicated.” Since the release of that brief, it hasn’t gotten any less complicated.
Long-time APC partner PCCA is our newest Diamond-level Corporate Patron for 2024 and has committed additional funding to sponsor a series APC regional meetings this year.
We presume that the Commissioner’s conflation of legitimate compounded drugs with illicit substances sold direct-to-consumer was inadvertent. Regardless, it requires a correction.
The number of APC Pharmacy-Facility Memberscontinues to grow (and grow and grow). We’ve added 23 since November, bringing the total number to 162.